Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05090904 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
A Phase 2 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT05090904 is a Phase 2 study that has completed, run by Insmed Incorporated. The registered enrollment target is 29 participants.
The verdict
NCT05090904, a Phase 2 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.
Interventions
- DRUG Placebo
- DRUG Brensocatib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05090904
The ClinicalTrials.gov registry entry for NCT05090904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05090904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05090904 about?
NCT05090904 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis". The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treat...
What is the current status of trial NCT05090904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2021-11-30. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT05090904?
The interventions under investigation include: Placebo (DRUG), Brensocatib (DRUG).
Who is sponsoring clinical trial NCT05090904?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.